argued that the advanced obligation to take delivery request, like in the center for global development (2005) it described in some critical kinds isflawed. Their nuclear criticism of the mechanism is that it is extremely difficult to specify the technical characteristics of a vaccine which is still some years away from development particularly if the condition of the science continual changes and the illness is complicated and varies between andwithin populations. This means in sequence the fact that it is possible that advanced obligation to take delivery is less cost effective programcould and by verses and on incentives could not have desirable effects. E.G. one of the technical characteristics, which could be specified, is the effectiveness of the vaccine, if about a length of time of we say it to protection two years granted. Assume that a vaccine it is developed in such a way that only 50% of the inoculated people seem to reach protection. This can raise two problems. If the partial effective decided inadmissible under the advanced obligation to take delivery plan to be paid vaccine is, despite getting the million people the immeasurable use for the health, the pioneer becomes not sufficiently balanced. But, if it is considered permissible (possibly only for a classified reward), the advanced could be used obligation to take delivery financing above in a short time, thus one second, which effective vaccine 100%, which could arrive was expected, two years later, reach no advanced obligation to take delivery aid at all. Thedifficulty is here that toundertake incentives of the enterprises are distorted researchonpotentially very valuable innovations: Enterprises have strong incentives for being sufficient to the technical requirements exactly but the very weak incentives for exceeding it or for developing useful vaccines, which do not meet it. The substantial problems lies in the requirement, so that the promoter specifies the characteristics of a product, which was not still developed: Flexibility is requested, because of the uncertainty; but flexibility inserts much discretion into the hands of the judging committee whether one an aid and if, howmuch pays. Farlow and its co-authors weight that such discretion makes the advanced obligation to take delivery program „for committee dangers “rather as „market-certainly. “Theproblemwith discretion is that medicine is linear nearly never in its effect on health. Adjustment authorities like theU.S. authority for the monitoring of food and drugs (FDA) form for investigations over, whether a given drug corresponds to its standards, only after the drug were clinically examined, but the standards, which are imposed by law for agreement of a drug, are not specifically: Drugs are, Safe “and „effective to be „. “The 4 of most pharmaceutical products has a distance of the effects, which would form to agree upon it very with difficulty, minimum standards in advance, since in reality there is a compromise between effectiveness and security: as noticed by the FDA (1999, P. 21-22), „a safe drug is one, that has For example, one OF the technical characteristics that might fuel element specified is the effectiveness OF the vaccine in giving protection over A by iodine OF, say, two years. Suppose A vaccine is developed look for that only 50% OF the people vaccinated appear ton obtain protection. This CAN raise two problem. If the partially effective vaccine is determined inadmissible ton of fuel element paid more under the Advanced Purchase Commitment flat, the pits bringing immense health benefits tons million OF people, the innovator is emergency adequately compensated. But, if it is deemed admissible (perhaps only for A scaled reward), the Advanced Purchase Commitment funding could fuel element used UP in A short time, then A that second, 100% effective vaccine expected ton arrive two years more later might obtain NO Advanced Purchase Commitment subsidy RK all. Thedifficulty here is that firms' incentives toundertake researchonpotentially very valuable innovation acres distorted: firms have strong incentives ton wants exactly meet the technical requirements, but very weak incentives ton exceed them or tons develop useful vaccines that DO emergency meet them. The essence OF the problem read into the requirements for the sponsor ton specify the characteristics OF A product that has emergency yet been developed: flexibility is required, because OF uncertainty; but flexibility PUTs A deal OF great in such a way discretion into the hands OF the Committee judging whether tons pay A subsidy, and if, howmuch. Farlow and his coauthors complain that look for discretion renders the Advanced Purchase Commitment program “Committee driven” than “market driven.” Theproblemwith discretion is that medicines of acres almost more never university-dimensionally in their impact on health. Regulatory of bodies look for as theU.S. Food and Drug administration (FDA) make determinations about whether A given drug meets their standards only after the drug has been clinically tested, but the standards imposed by law for approval OF A drug acres emergency specific: drugs acres tons of fuel element “safe” and “effective. ” 4 Most pharmaceuticals have A rank OF effects that would make it very difficult ton stipulate minimum standards into advance, since in effect there is A trade off between efficacy and safety: as noted by the FDA (1999, pp. 21-22), “A safe medical is one product that has